Moderna's stock tumbled 18% on Thursday after sales of its COVID-19 vaccine came in much lower than expected
It appears that $Pfizer(PFE)$ has taken the lead in the tug of war for market share among the leading COVID-19 vaccine makers, and Moderna's investors aren't happy about it.
Moderna Inc. ($(MRNA)$) this week had to disclose two pieces of disappointing news: its COVID-19 vaccine won't be authorized in teens or children in the U.S. before the end of the year, and supply issues getting its shot to different countries have sharply cut into sales as a result. we will be $60 soon...